

Special Issue

Childhood Leukemia

Message from the Guest Editors

Childhood leukemia is the most common malignancy in children. It encompasses several types of hematological malignancy, each with unique pathogeneses and treatment strategies. Clinical research led by clinical trial groups resulted in advanced therapeutic protocols. The development of targeted therapy as well as immunotherapy with chimeric antigen receptor T cells (CAR-T cell therapy) paved the way to a precision medicine approach. Advances in stem cell transplant protocols and techniques led to an improved outcome following this procedure. Clinically, further improvement of overall survival, understanding the long-term effects of chemotherapy, reducing racial health disparities in childhood leukemia, and advancing immunotherapy and stem cell transplantation are only some of the current challenges in this field. This Special Issue will highlight the basic, translational, and clinical aspects of childhood leukemia, along with the latest advances and future directions in understanding molecular mechanisms of pathogenesis, clinical presentation, and treatment of these diseases.

Guest Editors

Dr. Sinisa Dovat

Penn State College of Medicine, Hershey, United States

Dr. Karmen Stankov

Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

Deadline for manuscript submissions

closed (31 December 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/33438

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)